2Uharcek P. Prognostic factors in endometrial carcinoma [ J ]. J Obstet Gynaecol Res, 2008, 34:776-783.
3Price FV, Amin RM, Sumkin J. Complete clinical responses to neoad- juvant chemotherapy for uterine serous carcinoma [ J ]. Gynecol Oncol, 1999,73( 1 ) :140 - 144.
4Vandenput I,Van Calster B, Capoen A, et al. Neoadjuvant chemother- apy followed by interval debulking surgery in patients with serous en- dometrial cancer with transperitoneal spread ( stage IV ) : a new pre- ferred treatment[ J]. Br J Cancer,2009,101 (2) :244 - 249.
5Amant F,Vergote I. What is the role of neoadjuvant chemotherapy in advanced endometrial cancer [ J ]. Gynecol Oncol, 2010, 119 ( 3 ) 601 - 602.
6Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer [ J ]. Gynecol Ocol, 2011,121(1) :112 -117.
7Mitsuhashi A, Suzuka K, Yamasawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGF - C levels as tumor marker in patients with cervical carcinoma [ J]. Cancer,2005,103 (4) :724-730.
8Falou O, Sadeghi NA, Prematilake S, et al. Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography [ J ]. Transl Oncol,2013,6( 1 ) :17-24.
9De Marzi P,Frigerio L, Cipriani S,et al. Adjuvant treatment with concomitant radiotherapy and chemotherapy in high - risk endometrial cancer: a clinical experience [ J ]. Gyneeol Oncol, 2010,116(3) :408-412.
10Vandenput I, Van Calster B, Capoen A, et al. Neoadjuvant chemotherapy follow by interval debulking surgery in patients with serous endometrial cancer with transperitonel spread (stage IV ) :a new prefened treatment [J]. Brit J Cancer,2009,101 (2) :244- 249.
